Literature DB >> 20645073

Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes.

J A Johnson1, M Pollak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20645073     DOI： 10.1007/s00125-010-1855-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  32 in total

1.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.

Authors:  Mahvash Zakikhani; Ryan Dowling; I George Fantus; Nahum Sonenberg; Michael Pollak
Journal:  Cancer Res       Date:  2006-10-23       Impact factor: 12.701

2.  Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction.

Authors:  J C Heuson; N Legros
Journal:  Cancer Res       Date:  1972-02       Impact factor: 12.701

3.  Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.

Authors:  F Frasca; G Pandini; P Scalia; L Sciacca; R Mineo; A Costantino; I D Goldfine; A Belfiore; R Vigneri
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

4.  A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer.

Authors:  Veronica Vella; Giuseppe Pandini; Laura Sciacca; Rossana Mineo; Riccardo Vigneri; Vincenzo Pezzino; Antonino Belfiore
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

5.  Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase.

Authors:  Carolyn Algire; Lilian Amrein; Mahvash Zakikhani; Lawrence Panasci; Michael Pollak
Journal:  Endocr Relat Cancer       Date:  2010-06-01       Impact factor: 5.678

6.  Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients.

Authors:  Edoardo Mannucci; Matteo Monami; Daniela Balzi; Barbara Cresci; Laura Pala; Cecilia Melani; Caterina Lamanna; Ilaria Bracali; Michela Bigiarini; Alessandro Barchielli; Niccolo Marchionni; Carlo Maria Rotella
Journal:  Diabetes Care       Date:  2010-06-14       Impact factor: 17.152

7.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.

Authors:  Rangaswamy Govindarajan; Luke Ratnasinghe; Debra L Simmons; Eric R Siegel; Madhu V Midathada; Lawrence Kim; Peter J Kim; Randall J Owens; Nicholas P Lang
Journal:  J Clin Oncol       Date:  2007-04-20       Impact factor: 44.544

10.  Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types.

Authors:  Jack D Burton; David M Goldenberg; Rosalyn D Blumenthal
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964
View more
  19 in total

1.  Diabetes, insulin and cancer risk.

Authors:  Xi-Lin Yang; Juliana Cn Chan
Journal:  World J Diabetes       Date:  2012-04-15

Review 2.  Do statins cause diabetes?

Authors:  Mark R Goldstein; Luca Mascitelli
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

Review 3.  Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence.

Authors:  J A Johnson; B Carstensen; D Witte; S L Bowker; L Lipscombe; A G Renehan
Journal:  Diabetologia       Date:  2012-04-04       Impact factor: 10.122

Review 4.  Metformin and other biguanides in oncology: advancing the research agenda.

Authors:  Michael Pollak
Journal:  Cancer Prev Res (Phila)       Date:  2010-09-01

5.  Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.

Authors:  Ubaldo E Martinez-Outschoorn; Allison Goldberg; Zhao Lin; Ying-Hui Ko; Neal Flomenberg; Chenguang Wang; Stephanos Pavlides; Richard G Pestell; Anthony Howell; Federica Sotgia; Michael P Lisanti
Journal:  Cancer Biol Ther       Date:  2011-11-15       Impact factor: 4.742

6.  Diabetes-associated dysregulated cytokines and cancer.

Authors:  Yong Wu; Yanjun Liu; Yunzhou Dong; Jay Vadgama
Journal:  Integr Cancer Sci Ther       Date:  2016-02-15

7.  Protection from non-alcoholic steatohepatitis and liver tumourigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance.

Authors:  A Nakamura; K Tajima; K Zolzaya; K Sato; R Inoue; M Yoneda; K Fujita; Y Nozaki; K C Kubota; H Haga; N Kubota; Y Nagashima; A Nakajima; S Maeda; T Kadowaki; Y Terauchi
Journal:  Diabetologia       Date:  2012-09-07       Impact factor: 10.122

8.  Imbalance of angiogenesis in diabetic complications: the mechanisms.

Authors:  Zoya Tahergorabi; Majid Khazaei
Journal:  Int J Prev Med       Date:  2012-12

9.  Metformin and its clinical use: new insights for an old drug in clinical practice.

Authors:  Arrigo F G Cicero; Elisa Tartagni; Sibel Ertek
Journal:  Arch Med Sci       Date:  2012-11-07       Impact factor: 3.318

10.  Disease-specific mortality and secondary primary cancer in well-differentiated thyroid cancer with type 2 diabetes mellitus.

Authors:  Szu-Tah Chen; Chuen Hsueh; Wen-Ko Chiou; Jen-Der Lin
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.